PMLiVE20h
Roche’s Evrysdi tablet formulation granted FDA approval for spinal muscular atrophy
Roche has announced that a tablet formulation of its spinal muscular atrophy (SMA) treatment Evrysdi (risdiplam) has been ...
Zacks.com on MSN19h
Pharma Stock Roundup: NVS, ABBV M&A Deals, FDA Nod to RHHBY, PFE Drugs
Novartis NVS and AbbVie ABBV announced small M&A deals. The FDA approved the expanded use of Pfizer’s PFE cancer drug ...
Daily3h
USFDA Approves Roche's Evrysdi Tablet for Spinal Muscular Atrophy
Basel: Roche, announced that the U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for an ...
PharmiWeb22h
Orphan Drugs Market: A Comprehensive Analysis (2024-2035)
Market OverviewThe Orphan Drugs Market is a specialized sector within the pharmaceutical industry that focuses on the ...
Hosted on MSN13h
Top NIH Official Forced Out; Trump Sued by Fired HHS Watchdog; E. Coli Vaccine Flops
NIH's longtime second-in-command, Larry Tabak, DDS, PhD, was forced to retire from government service. (CBS News) When Robert ...
Healio15h
FDA approves Evrysdi tablets for spinal muscular atrophy
The FDA has approved Evrysdi in tablet form for patients with spinal muscular atrophy aged 2 years and older who weigh more ...
SMA18h
FDA approves new tablet version of oral SMA treatment Evrysdi
The U.S. Food and Drug Administration (FDA) has approved a new tablet formulation of Evrysdi (risdiplam), an approved oral ...